Literature DB >> 2155905

Congenital disorders of platelet function.

A K Rao1.   

Abstract

Platelets play a major role in normal hemostasis and congenital defects in platelet function are associated with bleeding manifestations that are largely mucocutaneous in origin and markedly variable in severity. They arise by different mechanisms and may be classified as disorders of: (1) platelet-agonist interaction, (2) platelet-vessel wall interaction (vWD and Bernard-Soulier syndrome), (3) platelet-platelet interaction (congenital afibrinogenemia and Glanzmann's thrombasthenia), (4) platelet secretion, and (5) platelet-coagulant protein interaction. Excluding vWD, most congenital platelet dysfunctions currently fall in the category of platelet secretion defects. Some of these patients have storage pool deficiency or defects in thromboxane synthesis, but the majority have normal granule stores. The underlying mechanisms in this large, heterogeneous group of dysfunctions remain to be elucidated. Bleeding episodes of vWD are managed by the administration of DDAVP or cryoprecipitate. The major treatment modality in the management of bleeding episodes and surgical procedures in patients with congenital platelet defects is platelet transfusions. Evidence is becoming available that many of these patients may respond to intravenous infusion of DDAVP with a shortening of the bleeding time. The specific groups of patients who will respond, and the efficacy of DDAVP in clinical situations remains to be established.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155905

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Hemostasis Laboratory: Assays for Platelet Function and Von Willebrand Disease.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

2.  Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses.

Authors:  J Gabbeta; X Yang; M A Kowalska; L Sun; N Dhanasekaran; A K Rao
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  The murine misty mutation: phenotypic effects on melanocytes, platelets and brown fat.

Authors:  E V Sviderskaya; E K Novak; R T Swank; D C Bennett
Journal:  Genetics       Date:  1998-01       Impact factor: 4.562

4.  Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.

Authors:  John H Cleator; Matthew T Duvernay; Michael Holinstat; Nancy E Colowick; Willie J Hudson; Yanna Song; Frank E Harrell; Heidi E Hamm
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

5.  Platelet function disorders.

Authors:  Gurjeewan Garewal; J Ahluwalia
Journal:  Indian J Pediatr       Date:  2003-12       Impact factor: 5.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.